292 related articles for article (PubMed ID: 28416841)
1. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
Li XN; Liu AH; Tang X; Ren Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
Li X; Wu Y; Liu A; Tang X
Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
[TBL] [Abstract][Full Text] [Related]
3. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
Wu C; Luo J
Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
[TBL] [Abstract][Full Text] [Related]
4. Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells.
Xu CG; Yang MF; Ren YQ; Wu CH; Wang LQ
Eur Rev Med Pharmacol Sci; 2016 Oct; 20(20):4362-4368. PubMed ID: 27831634
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1.
Zhu HY; Bai WD; Ye XM; Yang AG; Jia LT
Biochem Biophys Res Commun; 2018 Feb; 496(4):1308-1313. PubMed ID: 29408336
[TBL] [Abstract][Full Text] [Related]
6. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
Ren YQ; Wang HJ; Zhang YQ; Liu YB
Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.
Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X
PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766
[TBL] [Abstract][Full Text] [Related]
8. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
Li Z; Yu D; Li H; Lv Y; Li S
Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
[TBL] [Abstract][Full Text] [Related]
9. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
10. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
11. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
12. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X
Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173
[TBL] [Abstract][Full Text] [Related]
13. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
14. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
Ahmad A; Ginnebaugh KR; Yin S; Bollig-Fischer A; Reddy KB; Sarkar FH
BMC Cancer; 2015 Jul; 15():540. PubMed ID: 26206152
[TBL] [Abstract][Full Text] [Related]
15. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.
Wei Y; Lai X; Yu S; Chen S; Ma Y; Zhang Y; Li H; Zhu X; Yao L; Zhang J
Breast Cancer Res Treat; 2014 Sep; 147(2):423-31. PubMed ID: 25007959
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells.
Petri BJ; Piell KM; Wilt AE; Howser AD; Winkler L; Whitworth MR; Valdes BL; Lehman NL; Clem BF; Klinge CM
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37650685
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
[TBL] [Abstract][Full Text] [Related]
18. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
Shi YF; Lu H; Wang HB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
[TBL] [Abstract][Full Text] [Related]
19. Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b.
Fang Q; Chen X; Zhi X
Med Sci Monit; 2016 Oct; 22():3506-3513. PubMed ID: 27694794
[TBL] [Abstract][Full Text] [Related]
20. MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3.
Li X; Wu Y; Liu A; Tang X
Biochem Biophys Res Commun; 2016 Sep; 477(4):768-773. PubMed ID: 27363334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]